Search PubMed⌕ Search

Biomedical subjects

Zhou Wang

Publications and source records attributed to Zhou Wang.

38 records · Page 3Linked to original sources

Identification and characterization of a novel testosterone-regulated prominin-like gene in the rat ventral prostate.

More than two dozen androgen-responsive genes were identified from the castrated rat ventral prostate on the basis of their induction by exogenous testosterone. One of the identified genes encodes a novel 886-amino-acid protein that was named prominin-like protein 2 (PROML2) because it shares 32% identity to prominin and prominin-like protein 1, a family of important plasma membrane proteins with five transmembrane domains. The rat PROML2 gene is expressed abundantly in the glandular epithelial cells of the rat ventral prostate. The PROML2 gene is expressed in the human prostate and human prostate cancer cell lines with the highest level in less aggressive LNCaP cells and low expression in highly aggressive PC3 and DU145 cells, suggesting a correlation between PROML2 down-regulation and aggressiveness of prostate cancer cells. Transient transfection of green fluorescent protein-tagged rat PROML2 expression vector into prostate cancer cell lines showed that PROML2 protein is localized to the nuclear envelope and perinuclear region and induces cell death in all of the transfected prostate cancer cells. Taken together, our results argue that PROML2 is a novel proapoptotic membrane protein and its down-regulation may associate with aggressive phenotype of prostate cancer cells.

AC133 Antigen↗

[Gene diagnosis and prognosis of mediastinal lymph node occult micrometastasis in non-small cell lung carcinoma].

OBJECTIVE: To investigate gene diagnosis of occult micrometastasis in the mediastinal lymph node in patients with non-small cell lung carcinoma (NSCLC) and to evaluate its prognostic significance. METHODS: With mRNA expression of mucoid1 (MUC1) gene examined by RT-PCR, 168 mediastinal lymph nodes taken from 37 pN(0) (negative lymph nodes) NSCLC patients (stage Ia approximately IIb) made up the experiment group. Thrity negative lymph nodes from 14 benign lesions and 30 positive lymph nodes from 15 NSCLC patients served as control. The survival difference between MUC1 mRNA-negative and MUC1 mRNA-positive groups was compared by the chi(2) test. RESULTS: UC1 mRNA was not identified in the negative-control group (specificity = 100%), but it was identified in 26 of 30 positive-control samples (sensitivity = 86.7%). MUC1 mRNA was identified in 16 (9.5%) of the experiment group from 12 patients whose TNM stage was up-regulated to stage IIIa. The 3-year survival rate (58.3%) of MUC1 mRNA positive group patients with occult micrometastasis in mediastinal lymph node was lower than the 88.0% of MUC1 mRNA negative group (P < 0.05). CONCLUSION: Occult micrometastasis in the mediastinal lymph node in NSCLC patients can be diagnosed by MUC1 mRNA expression through RT-PCR. Poor prognosis in some pN(0) NSCLC patients may be associated with nodal occult micrometastasis.

Adult↗